FREMONT, Calif., July 30, 2024 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is excited to announce the opening of its European headquarters and distribution center in Milan, Italy. This strategic expansion marks a significant milestone in Alamar Biosciences’ commitment to advancing global scientific research through high-sensitivity biomarker solutions and supporting the commercialization of its ARGO™ HT System and NULISA™ Platform.
The new European headquarters will serve as the central hub for Alamar Biosciences’ operations across Europe, enhancing the company’s ability to provide innovative products and exceptional customer service to its growing base of European clients. The distribution center in Milan will ensure efficient and timely delivery of Alamar’s comprehensive range of proteomics products, reinforcing the company’s dedication to meeting the evolving needs of the global research community.
“We are thrilled to announce the opening of our European headquarters and distribution center in Milan,” said Yuling Luo, Ph.D., Chairman, Founder and CEO of Alamar. “This strategic expansion reflects our ongoing commitment to supporting the scientific community across Europe. Milan’s dynamic environment and strategic location will allow us to better serve our customers and accelerate the delivery of our innovative solutions.”
Key Highlights of the Expansion:
“Supporting our European research clients in a timely and efficient manner is essential to Alamar’s global success,” stated Luigi Pirovano, Managing Director, Alamar Biosciences Europe, srl. “Our logistical expertise, strategic location, and extensive experience in the life sciences sector will further enhance the entire customer experience with Alamar’s products and services.”
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
SOURCE Alamar Biosciences, Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…
London, United Kingdom--(Newsfile Corp. - November 25, 2024) - Edison issues report on Care REIT…
DUBAI, UAE, Nov. 25, 2024 /PRNewswire/ -- Hisense, a global leader in consumer electronics and…
VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the…
London, United Kingdom--(Newsfile Corp. - November 25, 2024) - Edison issues report on Theon International…
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…